Gregory Carven

Gregory Carven is a key researcher and inventor associated with the development of pembrolizumab, the active ingredient in the cancer treatment Keytruda. Initially focused on autoimmune diseases, his team pivoted to cancer therapy upon discovering the drug's potential to enhance immune responses against tumors.